ORPHA:440727
Combined hamartoma of the retina and retinal pigment epithelium
Also known as: CHR-RPE · Combined hamartoma of the retina and RPE
Publications
230
71.2th percentile
Trials
0
Interventional, condition-specific
Researchers
779
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A rare benign eye tumor characterized by the presence of glial cells, vascular tissue, and sheets of pigment epithelial cells lacking the distribution and organization of the normal retina and retinal pigment epithelium. The lesion is most commonly found unilaterally as a slightly elevated mass in a peripapillary location but can also occur in the macula or the retinal periphery. It is sometimes associated with neurofibromatosis type 1 or 2, nevoid basal cell carcinoma syndrome, or branchio-oculo-facial syndrome. Patients may be asymptomatic or present with loss of vision.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018607
- UMLS:C1862062
- NCIT:C174548
Additional Mondo synonyms (1)
combined hamartoma of the retina and RPE
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
230 matched papers (132 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
230
230 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
230 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
132 in the last 10 years · medium confidence · 71.2th percentile (publications denominator)
Phrase hits: 230 · MeSH hits: 0
Who's working on it?
779
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Shields CL22 papers · 2026
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Papers in Europe PMC - 02Shields JA12 papers · 2026
Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University , Philadelphia, PA,
Papers in Europe PMC - 03Chhablani J7 papers · 2026
Medical Retina and Vitreoretinal Surgery, University of Pittsburgh School of Medicine, 203 Lothrop Street, Suite 800, Pittsburg, PA 15213, USA.
Papers in Europe PMC - 04Kaliki S6 papers · 2026
Ocular Oncology Service, The Operation Eyesight Universal Institute for Eye Cancer (SK), Hyderabad, Telangana, India.
Papers in Europe PMC - 05
- 06Pappuru RR5 papers · 2021
Smt. Kanuri Santhamma Centre for Vitreo-Retinal Diseases.
Papers in Europe PMC - 07Cennamo G4 papers · 2017
Department of Neurosciences, Reproductive Sciences and Dentistry, Eye Clinic, University of Naples Federico II, Via S. Pansini 5, Naples 80133, Italy.
Papers in Europe PMC - 08Freund KB4 papers · 2021
Vitreous-Retina-Macula Consultants of New York, 460 Park Avenue, Fifth Floor, New York, 10022 NY USA.
Papers in Europe PMC - 09Fung AT4 papers · 2026
Westmead Hospital, Sydney, New South Wales, Australia; Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia; Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia.
Papers in Europe PMC - 10Arevalo JF3 papers · 2021
Retina Department, The King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia ; Retina Department, Wilmer Eye Institute, The Johns Hopkins University, Baltimore, MD, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Combined hamartoma of the retina and retinal pigment epithelium" OR "Combined hamartoma of retina and retinal pigment epithelium" OR "CHR-RPE" OR "Combined hamartoma of the retina and RPE" OR "Combined hamartoma of retina and RPE"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Combined hamartoma of the retina and retinal pigment epithelium" OR "Combined hamartoma of retina and retinal pigment epithelium" OR "CHR-RPE" OR "Combined hamartoma of the retina and RPE" OR "Combined hamartoma of retina and RPE"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (230) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium
Ingested 2026-07-27T16:22:32.606Z